scholarly journals The Role of MAPKs in B Cell Receptor-induced Down-regulation of Egr-1 in Immature B Lymphoma Cells

2006 ◽  
Vol 281 (52) ◽  
pp. 39806-39818 ◽  
Author(s):  
Jiyuan Ke ◽  
Murali Gururajan ◽  
Anupam Kumar ◽  
Alan Simmons ◽  
Lilia Turcios ◽  
...  
2009 ◽  
Vol 21 (4) ◽  
pp. 609-621 ◽  
Author(s):  
Maria Grandoch ◽  
Maider López de Jesús ◽  
Paschal A. Oude Weernink ◽  
Artur-Aron Weber ◽  
Karl H. Jakobs ◽  
...  

2016 ◽  
Vol 90 (21) ◽  
pp. 9782-9796 ◽  
Author(s):  
Lingbing Tan ◽  
Chaocan Zhang ◽  
Julien Dematos ◽  
Linlin Kuang ◽  
Jae U. Jung ◽  
...  

ABSTRACTWhile CD95 is an apoptosis-inducing receptor and has emerged as a potential anticancer therapy target, mounting evidence shows that CD95 is also emerging as a tumor promoter by activating nonapoptotic signaling pathways. Gammaherpesviral infection is closely associated with lymphoproliferative diseases, including B cell lymphomas. The nonapoptotic function of CD95 in gammaherpesvirus-associated lymphomas is largely unknown. Here, we show that stimulation of CD95 agonist antibody drives the majority of sensitive gammaherpesvirus-transformed B cells to undergo caspase-dependent apoptosis and promotes the survival and proliferation of a subpopulation of apoptosis-resistant B cells. Surprisingly, CD95-mediated nonapoptotic signaling induced beta interferon (IFN-β) expression and correlatively inhibited B cell receptor (BCR)-mediated gammaherpesviral replication in the apoptosis-resistant lymphoma cells without influencing BCR signaling. Further analysis showed that IFN-β alone or synergizing with CD95 blocked the activation of lytic switch proteins and the gene expression of gammaherpesviruses. Our findings indicate that, independent of its apoptotic activity, CD95 signaling activity plays an important role in blocking viral replication in apoptosis-resistant, gammaherpesvirus-associated B lymphoma cells, suggesting a novel mechanism that indicates how host CD95 prototype death receptor controls the life cycle of gammaherpesviruses independent of its apoptotic activity.IMPORTANCEGammaherpesviruses are closely associated with lymphoid malignancies and other cancers. Viral replication and persistence strategies leading to cancer involve the activation of antiapoptotic and proliferation programs, as well as evasion of the host immune response. Here, we provide evidence that the stimulation of CD95 agonist antibody, mimicking one of the major mechanisms of cytotoxic T cell killing, inhibits B cell receptor-mediated gammaherpesviral replication in CD95 apoptosis-resistant lymphoma cells. CD95-induced type I interferon (IFN-β) contributes to the inhibition of gammaherpesviral replication. This finding sheds new light on the CD95 nonapoptotic function and provides a novel mechanism for gammaherpesviruses that helps them to escape host immune surveillance.


Blood ◽  
2006 ◽  
Vol 108 (9) ◽  
pp. 3135-3142 ◽  
Author(s):  
Jonathan M. Irish ◽  
Debra K. Czerwinski ◽  
Garry P. Nolan ◽  
Ronald Levy

Abstract The B-cell receptor (BCR) transmits life and death signals throughout B-cell development, and altered BCR signaling may be required for survival of B-lymphoma cells. We used single-cell signaling profiles to compare follicular lymphoma (FL) B cells and nonmalignant host B cells within individual patient biopsies and identified BCR-mediated signaling events specific to lymphoma B cells. Expression of CD20, Bcl-2, and BCR light chain isotype (κ or λ) distinguished FL tumor B-cell and nontumor host B-cell subsets within FL patient biopsies. BCR-mediated signaling via phosphorylation of Btk, Syk, Erk1/2, and p38 occurred more rapidly in tumor B cells from FL samples than in infiltrating nontumor B cells, achieved greater levels of per-cell signaling, and sustained this level of signaling for hours longer than nontumor B cells. The timing and magnitude of BCR-mediated signaling in nontumor B cells within an FL sample instead resembled that observed in mature B cells from the peripheral blood of healthy subjects. BCR signaling pathways that are potentiated specifically in lymphoma cells should provide new targets for therapeutic attention.


1995 ◽  
Vol 25 (5) ◽  
pp. 1352-1357 ◽  
Author(s):  
Michael S. K. Choi ◽  
Lawrence H. Boise ◽  
Alexander R. Gottschalk ◽  
José Quintans ◽  
Craig B. Thompson ◽  
...  

2000 ◽  
Vol 164 (3) ◽  
pp. 1306-1313 ◽  
Author(s):  
Stéphane Denépoux ◽  
Nathalie Fournier ◽  
Catherine Péronne ◽  
Jacques Banchereau ◽  
Serge Lebecque

Sign in / Sign up

Export Citation Format

Share Document